Taipei, Taiwan, 15 August 2025 — Lotus Pharmaceutical Co., Ltd. (“Lotus”, TWSE Stock Code: 1795), a leading multinational pharmaceutical company, proudly announces its continued recognition as one of Asia’s most exemplary employers, securing the “HR Asia Best Companies to Work for in Asia – Taiwan Region” award for a fourth year in a row. This milestone underscores Lotus’s enduring commitment to cultivating a people-first, purpose-driven workplace culture where employees thrive and innovation flourishes.
This year, Lotus also garnered accolades in three additional HR Asia award categories, reflecting the Company’s well-rounded dedication to its workforce and values:
· HR Asia Diversity, Equity & Inclusion Award (2nd time winner)
· HR Asia Sustainable Workplace Award (1st time)
· HR Asia Tech Empowerment Award (1st time)
These honors are a testament to Lotus’s strategic focus on empowering talent, fostering an inclusive environment, advancing sustainability, and leveraging technology to elevate the employee experience.
“At Lotus, we believe that a healthy organisation begins with a healthy, supported workforce,” said Petar Vazharov, Chief Executive Officer of Lotus Pharmaceutical. “These awards are more than symbols of achievement – they proof that our investment in people, purpose, and progress is making a lasting impact. We are deeply honoured and even more motivated to keep raising the bar.”
As Lotus continues to expand its global footprint and evolve as a force in the international pharmaceutical landscape, it remains steadfast in championing progressive HR practices. With a diverse team representing around 26 nationalities, a near-equal gender distribution in leadership roles, and a growing commitment to sustainability and digital transformation, Lotus is redefining what it means to be a modern, forward-thinking employer in Asia and beyond.
About Lotus
Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with a global presence, focused on commercializing both novel and generic pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company boasts a best-in-class R&D and manufacturing platform in Asia, certified by leading regulatory authorities around the world, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus has established partnerships in nearly every major global market, including the U.S., Europe, Japan, China, and Brazil. The company is currently developing and registering over 100 strategically selected pharmaceutical projects across Asia and the U.S., with more than 250 commercial products. Lotus invests in a diversified portfolio, consisting of high-barrier oncology, complex generics, 505(b)2, NCEs, and biosimilars, through both internal R&D investments and licensing-in partnerships to strengthen its portfolio competitiveness.
Media Inquiries:
Yihsuan Kuo, Investor Relations Assistant Manager
Jeffrey Tsang, Head of Investor Relations and Corporate Communications
+886 2 2700 5908
investor@lotuspharm.com